MAP Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP
Announces Investigation Of Acquisition By Allergan, Inc.
NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Bernstein
Liebhard LLP is investigating whether the Board of Directors of MAP
Pharmaceuticals, Inc. ("MAP Pharmaceuticals" or the "Company")
(NASDAQ: MAPP) breached its fiduciary duty to its shareholders in
agreeing to sell MAP Pharmaceuticals to Allergan, Inc. (NYSE:
AGN).
(Logo:
http://photos.prnewswire.com/prnh/20120202/MM47134LOGO)
Under the terms of the agreement, MAP Pharmaceuticals
shareholders will receive $25.00 in
cash for each share they own. The investigation is focused on
the potential unfairness of the price to MAP Pharmaceuticals
shareholders and the process by which the MAP Pharmaceuticals Board
of Directors considered and approved the transaction.
If you are interested in discussing your rights as a MAP
Pharmaceuticals stockholder, with no obligation or cost to you,
please contact U. Seth Ottensoser
at:
(877) 779-1414
or
Ottensoser@bernlieb.com.
Bernstein Liebhard LLP has pursued hundreds of securities,
consumer and shareholder rights cases and recovered over
$3 billion for its clients. It
has been named to The National Law Journal's "Plaintiffs'
Hot List" in each of the last ten years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
www.bernlieb.com
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The
law firm responsible for this advertisement is Bernstein Liebhard
LLP, 10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for
this advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
SOURCE Bernstein Liebhard LLP